Phase 3 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been newly diagnosed with glioblastoma (a type of brain tumour) based on the 2021 World Health Organization classification
- People whose diagnosis was confirmed no more than 4 weeks before being enrolled in the trial
- People aged 70 years or older
- People who have had a brain scan (MRI with contrast dye) within 72 hours of their surgery
- People whose tumour has been tested for a specific genetic marker called MGMT promoter methylation status (confirm with trial site)
- People with a Karnofsky performance score of 60 or higher — this is a measure of general physical ability and functioning (confirm with trial site)
- People who are on a stable or reducing dose of steroids, if they are taking them
- People who have not previously had radiotherapy to the brain
- People who have not previously had any chemotherapy
- People whose blood, kidney, and liver results are healthy enough to safely receive a chemotherapy drug called temozolomide
- People who are able to begin radiotherapy within 3 weeks of being enrolled in the trial
Who may not be able to join:
- People who have cancer that has spread to the lining of the spine
- People who have a history of another cancer, unless it was: cervical carcinoma in situ (a very early-stage cervical condition), a non-melanoma skin cancer that was fully removed, or a cancer with no signs of return for 5 years or more
- People who have a serious active infection or other significant underlying health conditions
- People with psychological difficulties that would make it hard to follow the trial's requirements
- People who are known to be allergic to temozolomide or chemically similar drugs
- People who are currently taking part in another clinical trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Chan Woo Wee, MD, PhD, Severance Hospital
Phone: +82-2-2228-8121
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Overall survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.